Advertisement

 

 

Performance Evaluation of the MyT4 Technology for Determining ART Eligibility.

Performance Evaluation of the MyT4 Technology for Determining ART Eligibility.
Author Information (click to view)

Sitoe N, Macamo R, Meggi B, Tobaiwa O, Loquiha O, Bollinger T, Vojnov L, Jani I,


Sitoe N, Macamo R, Meggi B, Tobaiwa O, Loquiha O, Bollinger T, Vojnov L, Jani I, (click to view)

Sitoe N, Macamo R, Meggi B, Tobaiwa O, Loquiha O, Bollinger T, Vojnov L, Jani I,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

PloS one 2016 Oct 2511(10) e0165163 doi 10.1371/journal.pone.0165163

Abstract
BACKGROUND
In resource-limited countries, CD4 T-cell (CD4) testing continues to be used for determining antiretroviral therapy (ART) initiation eligibility and opportunistic infection monitoring. To support expanded access to CD4 testing, simple and robust technologies are necessary. We conducted this study to evaluate the performance of a new Point-of-Care (POC) CD4 technology, the MyT4, compared to conventional laboratory CD4 testing.

METHODS
EDTA venous blood from 200 HIV-positive patients was tested in the laboratory using the MyT4 and BD FACSCalibur™.

RESULTS
The MyT4 had an r2 of 0.82 and a mean bias of 12.3 cells/μl. The MyT4 had total misclassifications of 14.7% and 8.8% when analyzed using ART eligibility thresholds of 350 and 500 cells/μl, respectively.

CONCLUSIONS
We conclude that the MyT4 performed well in classifying patients using the current ART initiation eligibility thresholds in Mozambique when compared to the conventional CD4 technology.

Submit a Comment

Your email address will not be published. Required fields are marked *

eighteen + nineteen =

[ HIDE/SHOW ]